Major study finds low infection rates for Aroa’s Myriad bioscaffold | Stockhead

Aroa (ASX:ARX) has strengthened the clinical case for its Myriad bioscaffold products after a major study reported low infection rates.

Continue in Briflio to read, react, comment, and share.